ArticleJournal of Korean medical science2015
Agmatine Attenuates Brain Edema and Apoptotic Cell Death after Traumatic Brain Injury.
Article in Journal of Korean medical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Agmatinase Facilitates Gastric Cancer Tumorigenesis Through PI3K/AKT-Mediated Enhancement of Proliferation, Invasion, and Stemness.Applied biochemistry and biotechnology · 2026Article
- Aquaporins in Acute Brain Injury: Insights from Clinical and Experimental Studies.Biomedicines · 2025Review
- Aquaporin‑1 regulates microglial polarization and inflammatory response in traumatic brain injury.International journal of molecular medicine · 2025Article
- Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo-1 and Inflammatory Pathways.Brain and behavior · 2025Article
- Overexpression of aquaporin-1 plays a vital role in proliferation, apoptosis, and pyroptosis of Wilms' tumor cells.Journal of cancer research and clinical oncology · 2024Article
- Maintenance of the Neuroprotective Function of the Amino Group Blocked Fluorescence-Agmatine.Neurochemical research · 2021Article
- Role of agmatine in the application of neural progenitor cell in central nervous system diseases: therapeutic potentials and effects.Anatomy & cell biology · 2021Review
- Pathogenic Functions of Tumor Necrosis Factor Receptor-Frontiers in molecular neuroscience · 2021Article
- Agmatine Alleviates Epileptic Seizures and Hippocampal Neuronal Damage by Inhibiting Gasdermin D-Mediated Pyroptosis.Frontiers in pharmacology · 2021Article
- Targeted Delivery of Iron Oxide Nanoparticle-Loaded Human Embryonic Stem Cell-Derived Spherical Neural Masses for Treating Intracerebral Hemorrhage.International journal of molecular sciences · 2020Article
- Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors.Neurochemical research · 2019Review
- Neuroprotective Role of Agmatine in Neurological Diseases.Current neuropharmacology · 2018Review
- Endogenous Agmatine Induced by Ischemic Preconditioning Regulates Ischemic Tolerance Following Cerebral Ischemia.Experimental neurobiology · 2017Article
- Simulating vasogenic brain edema using chronic VEGF infusion.Journal of neurosurgery · 2017Article
- Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury.Molecular medicine reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is associated with poor neurological outcome, including necrosis and brain edema. In this study, we investigated whether agmatine treatment reduces edema and apoptotic cell death after TBI. TBI was produced by cold injury to the cerebral primary motor cortex of rats. Agmatine was administered 30 min after injury and once daily until the end of the experiment. Animals were sacrificed for analysis at 1, 2, or 7 days after the injury. Various neurological analyses were performed to investigate disruption of the blood-brain barrier (BBB) and neurological dysfunction after TBI. To examine the extent of brain edema after TBI, the expression of aquaporins (AQPs), phosphorylation of mitogen-activated protein kinases (MAPKs), and nuclear translocation of nuclear factor-κB (NF-κB) were investigated. Our findings demonstrated that agmatine treatment significantly reduces brain edema after TBI by suppressing the expression of AQP1, 4, and 9. In addition, agmatine treatment significantly reduced apoptotic cell death by suppressing the phosphorylation of MAPKs and by increasing the nuclear translocation of NF-κB after TBI. These results suggest that agmatine treatment may have therapeutic potential for brain edema and neural cell death in various central nervous system diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.